8-K/A: Alumis Completes ACELYRIN Merger, Reveals Financials and Strategic Shift

Alumis Inc. has finalized its merger with ACELYRIN, Inc., integrating ACELYRIN's operations and product pipeline, while ACELYRIN's latest financial disclosures reveal significant losses, a strategic pivot away from izokibep development, and ongoing litigation.

Summary

• Alumis Inc. completed its merger with ACELYRIN, Inc. on May 21, 2025, with ACELYRIN becoming a wholly-owned subsidiary.
• The merger involved Alumis issuing 48,653,549 shares of its common stock and assuming ACELYRIN's stock options and restricted stock units, at an exchange ratio of 0.4814 Alumis shares for each ACELYRIN share.
• Alumis recognized a preliminary gain on bargain purchase of $210.8 million, as ACELYRIN's market value was trading below its net assets at the time of the merger agreement.
• ACELYRIN reported a net loss of $248.2 million for the year ended December 31, 2024, and $55.3 million for the three months ended March 31, 2025.
• Cash used in ACELYRIN's operating activities was $303.9 million for the year ended December 31, 2024, and $39.0 million for the three months ended March 31, 2025.
• As of March 31, 2025, ACELYRIN had cash, cash equivalents, restricted cash, and short-term marketable securities totaling $411.1 million.
• ACELYRIN's accumulated deficit reached $736.9 million by December 31, 2024, and $792.2 million by March 31, 2025.
• ACELYRIN implemented a restructuring plan in August 2024, reducing its workforce by 40 people (approximately one-third of its headcount) and incurring $11.4 million in restructuring charges for the year ended December 31, 2024.
• The company suspended new internal investment in izokibep for hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA), terminating its license agreement with Affibody AB effective January 31, 2025.
• ACELYRIN is now primarily focusing its efforts on the lonigutamab clinical program for thyroid eye disease (TED).
• In October 2024, Pierre Fabre exercised its buy-out option under the lonigutamab agreement, resulting in a one-time payment of $31.0 million from ACELYRIN.
• ACELYRIN recorded $37.0 million in other income in Q1 2024 from vendor arrangements ($30.0 million cash payment + $5.0 million service credit) and an asset sale to Tenet Medicines, Inc. ($7.0 million cash).
• A non-cash impairment expense of $2.9 million was recognized in Q1 2025 related to the sublease of ACELYRIN's South San Francisco office.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to ACELYRIN's substantial and ongoing net losses, high cash burn, significant restructuring efforts including workforce reduction and program termination, and pending litigation. While the merger with Alumis and the resulting bargain purchase gain are positive for Alumis, ACELYRIN's underlying operational performance and financial health prior to the merger, as detailed in the filing, present significant challenges and risks.

Positives

• Alumis recognized a preliminary gain on bargain purchase of $210.8 million from the acquisition of ACELYRIN, indicating the acquisition was at a favorable price relative to ACELYRIN's net assets.
• ACELYRIN received $30.0 million in cash and a $5.0 million service credit from vendor arrangements in March 2024, and $7.0 million cash from an asset sale in January 2024, contributing to other income.
• The strategic decision to focus primarily on the lonigutamab clinical program in thyroid eye disease (TED) allows for a more concentrated allocation of resources.

Negatives

• ACELYRIN incurred significant net losses of $248.2 million in 2024 and $55.3 million in Q1 2025, contributing to a growing accumulated deficit of $792.2 million as of March 31, 2025.
• Cash used in operating activities was substantial, totaling $303.9 million in 2024 and $39.0 million in Q1 2025, indicating a high cash burn rate.
• A restructuring plan in August 2024 led to a workforce reduction of approximately one-third (40 people) and $11.4 million in restructuring charges.
• The company suspended new internal investment in izokibep for HS, PsA, and AxSpA, terminating the Affibody Agreement, which represents a significant shift away from a previously pursued product candidate.
• A $31.0 million payment was made to Pierre Fabre in October 2024 due to the exercise of a buy-out option, impacting liquidity.
• A non-cash impairment expense of $2.9 million was recorded in Q1 2025 due to the sublease of office space, reflecting a reduction in asset value.

Risks

• The company has incurred significant losses and negative cash flows from operations since its inception and expects to continue incurring substantial losses, with no assurance of achieving or sustaining profitability.
• The ability to achieve and sustain profitability depends on successfully developing, obtaining regulatory approval for, and commercializing product candidates, which is uncertain.
• Unless additional capital is raised, the company may have to delay, reduce the scope of, or eliminate research or development programs.
• A federal securities class action lawsuit alleges misleading investors about the Phase 2b trial of izokibep in HS, with the potential for significant defense costs and material financial impact.
• The company is subject to risks related to the timing and ability to advance product candidates through clinical development, costs and timelines for manufacturing clinical supplies, regulatory approval, market acceptance, and reimbursement.
• Reliance on third-party vendors, competition from companies with greater resources, protection of intellectual property, and the ability to attract and retain employees are ongoing risks.

Future Outlook

Management expects that its current cash, cash equivalents, and short-term marketable securities will be sufficient to fund its operating plan and capital expenditure requirements for at least the next 12 months from the date of issuance of the consolidated financial statements. The company anticipates continuing to incur significant and increasing expenses and substantial losses as it develops and seeks regulatory approvals for product candidates, expands its pipeline, and invests in its organization. Achieving and sustaining profitability is uncertain and will depend on successful product development, regulatory approval, and commercialization. Additional capital will be required unless revenue generation commences.

Management Comments

• Management expects that its cash and cash equivalents and short-term marketable securities will be sufficient to fund its current operating plan and capital expenditure requirements for at least the next 12 months from the date of issuance of these consolidated financial statements.

Industry Context

The biopharma industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. ACELYRIN's strategic shift from multiple indications for izokibep to a primary focus on lonigutamab for thyroid eye disease reflects the common industry practice of prioritizing promising assets and streamlining pipelines to optimize resource allocation and accelerate time to market for specific indications. The merger with Alumis is a consolidation move, common in the biopharma sector, aimed at leveraging combined resources and potentially achieving greater scale or pipeline diversification.

Management Changes

Corporate Governance

Legal Proceedings

• A federal securities class action lawsuit, Boukadoum v. Acelyrin, Inc. et al. (No. 2:23-cv-09672-FMO-MAA), was commenced on November 15, 2023, in the U.S. District Court for the Central District of California.
• The amended complaint, filed March 26, 2024, alleges that ACELYRIN and its current/former executive officers and directors violated the Exchange Act and Securities Act by misleading investors about the Phase 2b trial results of izokibep in HS.
• The lawsuit seeks damages and an award of reasonable costs and expenses, including attorneys' fees and expert fees.
• Defendants filed a motion to dismiss the amended complaint on May 3, 2024, which is currently pending.
• The outcome of this lawsuit is uncertain, and the company cannot estimate the possible loss, but it could be material, even if the company prevails.

Stakeholder Impact

• Shareholders: The merger with Alumis involves an exchange of shares, potentially impacting ownership structure and future value. The gain on bargain purchase is a positive for Alumis's balance sheet. The ongoing class action lawsuit poses a financial risk and uncertainty.
• Employees: ACELYRIN's restructuring plan resulted in a workforce reduction of approximately one-third (40 people), leading to severance payments and job losses. Remaining employees will be integrated into Alumis, with some stock awards accelerated or modified.
• Customers/Patients: The strategic shift to focus on lonigutamab for thyroid eye disease means that development for izokibep in HS, PsA, and AxSpA has been suspended, potentially impacting future treatment options for patients in those areas.
• Suppliers/Vendors: Contract terminations and cancellations, such as the supply agreement termination ($14.3 million cost) and manufacturing agreement cancellation ($7.2 million net charge), affect vendor relationships and obligations.
• Creditors: The company's significant accumulated deficit and ongoing cash burn highlight financial challenges, which could be a concern for creditors, although management expects sufficient liquidity for the next 12 months.

Next Steps

• Alumis will continue to integrate ACELYRIN's operations as a wholly-owned subsidiary.
• The primary focus of the combined entity's clinical development will be on the lonigutamab program for thyroid eye disease (TED).
• The federal securities class action lawsuit against ACELYRIN and its former officers/directors will proceed, with a motion to dismiss currently pending.
• Converted performance RSUs will vest in two equal installments on May 15, 2026, and May 15, 2027, subject to continued service.

Key Dates

Recommendation

Keywords

Biopharma, Merger, Acquisition, SEC Filing, Financial Results, Clinical Trials, Drug Development, Izokibep, Lonigutamab, Thyroid Eye Disease, Hidradenitis Suppurativa, Psoriatic Arthritis, Axial Spondyloarthritis, Restructuring, Litigation, Capital Raise, Biotechnology, Pharmaceuticals, SEC 8-K/A